The drastic reduction in indirect costs is not a path to innovation or cost savings — it’s a threat to U.S.’s position as ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...